MiR-146a contributes to resistance to doxorubicin in breast cancer by altering cell signaling and apoptosis and similarly influences resistance to cisplatin in non-small cell lung cancer (NSCLC) through the NF-κB pathway. Here, NFKB1 is linked to non-small cell lung carcinoma.